Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | SCD | O00767 | 7/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222045 | 0.87 | NPY5R (0.48) | SIGMAR1OPRM1SCDADRA1ANPY5R | |
| SCHEMBL3226254 | 0.85 | NPY5R (0.45) | SIGMAR1OPRM1SCDADRA1ANPY5R | |
| SCHEMBL3229036 | 0.81 | SCD (0.45) | SIGMAR1OPRM1SCDADRA1ANPY5R | |
| SCHEMBL3219732 | 0.80 | SCD (0.43) | SIGMAR1OPRM1SCDADRA1ANPY5R | |
| SCHEMBL3230543 | 0.79 | SCD (0.47) | SCDADRA1ANPY5RKCNH2DGAT1 | |
| SCHEMBL3222120 | 0.78 | SCD (0.47) | SIGMAR1OPRM1SCDADRA1ANPY5R | |
| SCHEMBL3228366 | 0.76 | SCD (0.61) | SIGMAR1OPRM1SCD | |
| SCHEMBL3225247 | 0.75 | SCD (0.48) | OPRM1SCD | |
| SCHEMBL3230535 | 0.75 | SCD (0.49) | SIGMAR1SCDADRA1A | |
| SCHEMBL3216485 | 0.74 | SCD (0.48) | SCDCNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575167-B2 | Spiro compounds having stearoyl-CoA desaturase action | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069351-A1 | SPIRO COMPOUND AND USE THEREOF | SCD, SPR, SCD5 | SIGMAR1 1459/4885OPRM1 2864/4885SCD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.